A 40-year-old male patient was diagnosed with BCR-ABL1 positive chronic stage CML 2 years ago and achieved complete molecular response on nilotinib, which was switched to dasatinib due to nilotinib intolerance. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.